Jinmatris Signs Agreement with Ministry of Health and Welfare to Support Hepatitis A Vaccine Clinical Trials

Jinmatris has been selected for the Ministry of Health and Welfare's Vaccine Industrialization Technology Development Project, supporting the localization of essential vaccination production.

According to Jinmatris on September 14, this government support project will assist in developing a hepatitis A vaccine. The total project cost for the clinical assignment under the agreement is 3,112,000,000 won.

Jinmatris has established immunogenicity and efficacy data, as well as non-clinical safety data, for its hepatitis A vaccine candidate 'GMAI-02.' Last year, in the first half, the company obtained Investigational New Drug (IND) approval for phase 1 clinical trials from the Ministry of Food and Drug Safety. The company has now designated the clinical trial institution for the next-generation hepatitis A vaccine GMAI-02 and plans to begin phase 1 clinical trials in the second half of 2026. Based on the results from phase 1, Jinmatris intends to seek IND approval for phase 2 clinical trials.

Suok Kim, CEO of Jinmatris, stated, "By securing funding for clinical trials through this Ministry of Health and Welfare support agreement, we have established a foundation that will enable us to advance our clinical development more stably going forward. It is significant that GMAI-02 has progressed beyond research and development into full-scale clinical trials, marking an important milestone for the company."

This content was produced with the assistance of AI translation services.